July 24 (Bloomberg) -- Eli Lilly & Co., the maker of the antidepressant Cymbalta and diabetes treatment Humalog, raised its full-year guidance after second-quarter sales grew faster than expected and cost-cutting programs took effect. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
This text has been automatically generated. It may not be 100% accurate.